Masitinib (CAS 790299-79-5)-also known as Masitinib mesylate -is a next-generation tyrosine kinase inhibitor (TKI) with therapeutic value in both research and veterinary medicine. Developed as a highly selective oral TKI, Masitinib targets key signaling pathways involved in cancer progression , mast cell activation , and chronic inflammation . Its precision and potency make it a significant API for the treatment of animal mast cell tumors and other immune-mediated disorders.

Product Details & Chemical Information

Masitinib belongs to multiple pharmacologically relevant classes, including benzamides , piperazines , 1,3-thiazoles , and pyridines , giving it a complex structure optimized for kinase inhibition.

What is Masitinib?

Masitinib is a highly selective oral tyrosine kinase inhibitor designed to block the activity of:

• Platelet-derived growth factor receptors (PDGFR-α/β)
• Stem cell factor receptor (c-Kit)
• Lyn and Fyn tyrosine kinases involved in mast cell activation

These pathways are central to tumor growth, metastasis, and pathological inflammatory responses. By inhibiting them, Masitinib helps slow disease progression and reduce inflammatory reactions.

While widely explored in human medicine for conditions such as multiple myeloma , gastrointestinal stromal tumors , and systemic mastocytosis , masitinib also holds strong potential and active use in veterinary oncology and immunology .

Veterinary Applications

✔ Treatment of Mast Cell Tumors in Animals

Mast cell tumors are among the most common and aggressive cancers in dogs. Masitinib's selective inhibition of c-Kit receptors -critical regulators of mast cell survival-makes it an effective therapeutic option.

✔Management of Chronic Inflammatory Disorders

Masitinib helps reduce mast cell–mediated inflammation, supporting treatment of:

• Chronic allergic diseases
• Atopic dermatitis
• Immune-mediated inflammatory conditions

✔ Potential for Broader Veterinary Oncology Use

Ongoing research suggests Masitinib may have value in treating:

• Melanoma
• Soft-tissue sarcomas
• Other c-Kit–driven malignancies

Its role continues to expand as studies reveal new therapeutic possibilities.

Mechanism of Action

Masitinib works by selectively blocking tyrosine kinases -enzymes that regulate cell signaling, proliferation, and immune activation. Key effects include:

• Inhibiting tumor cell growth
• Preventing abnormal mast cell activation
• Reducing inflammatory cytokine release
• Slowing cancer cell survival pathways

This makes masitinib a valuable tool for managing both neoplastic and inflammatory veterinary diseases.

Manufacturing Quality & Formulation

As an active pharmaceutical ingredient (API), masitinib must undergo:

• Strict in-house quality testing
• Purity and potency validation
• Good Manufacturing Practice (GMP) procedures

Its stability and molecular properties allow it to be formulated into various oral dosage forms for veterinary use.

About the Manufacturer

Our production facility is located in Zhumadian City, Henan Province, China , established in 2019. With advanced equipment and professional R&D capabilities, we supply high-quality APIs such as Masitinib to:

• Europe
• South America
• The Middle East
• Asia

Our products have earned consistent praise from domestic and international partners.

Frequently Asked Questions (FAQs)

Q: Where is your factory located?

A: In Zhumadian City, Henan Province, China.

Q: When was your factory established?

A: Our facility was built in 2019.

Q: Which markets do you supply most frequently?

A: Europe, South America, the Middle East, and Asia are our main markets, with excellent customer feedback.

Conclusion

Masitinib (CAS 790299-79-5) is a highly selective tyrosine kinase inhibitor with powerful applications in veterinary oncology and inflammatory disease treatment. Its well-defined mechanism, strong therapeutic potential, and growing clinical relevance make it an important API for modern veterinary pharmaceutical products.

With ongoing global research and expanding market adoption, masitinib is positioned to remain a cornerstone compound for managing mast cell–related diseases and various cancers in animals.